ZDF
Sign inSign up

Vulnerabilities

Vulnerability · CVE-2025-9719

A weakness has been identified in O2OA up to 10.0-410.

Published Aug 31, 2025 · catalog updated Oct 19, 2026 · A weakness has been

Open the advisory

Exploitation likelihood is not on this record for CVE-2025-9719. A missing EPSS score is not a low risk. Compare A weakness has been with the linked advisory before you change production.

Gaps on this record

  • The stored product name is a package slug. The name on this page is taken from the title (A weakness has been).
  • No version range is stored. A customer cannot check an installed version against this record.
  • No vendor fix or required action is stored. Compare the linked advisory before you change production.
  • EPSS is missing. A missing score is not a low risk.
Severity
Low2.0
Known exploitation
Not in CISA/VulnCheck KEV
EPSS
Awaiting synchronization with FIRST
Remediation
Advisory link
Affected products
cpe zoneland/o2oa

A weakness has been identified in O2OA up to 10.0-410. This vulnerability affects unknown code of the file /x_processplatform_assemble_designer/jaxrs/script of the component Personal Profile Page. Executing manipulation of the argument name/alias/description/applicationName can lead to cross site scripting. The attack can be executed remotely. The exploit has been made available to the public and could be exploited.

Are you affected?

Enter the version you run. The result uses only the ranges stored on this record.

The check returns affected, not affected, or incomplete. It does not guess a version that is missing from the record.

  • cpe zoneland/o2oaversion unspecified

How to fix CVE-2025-9719

What to do

Three questions, each answered from this record only. Confirm the vendor advisory before you patch.

Should you patch?

Exploitation likelihood is not on this record for CVE-2025-9719. A missing EPSS score is not a low risk. Compare A weakness has been with the linked advisory before you change production.

Which versions are affected?

Affected version ranges are not on this record. Compare the installed version with the linked vendor advisory before you change production.

What should an analyst verify?

CWE-79: Cross-site Scripting (XSS); CWE-94: Code Injection. EPSS is not on this record yet. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.

Code

The project this record applies to. Exploit listings stay in References.

No public source repository is identified for this product.

Timeline

Detection, updates, and resolution for this record.

  1. Aug 31, 2025 · NIST NVD

    Detected

    A weakness has been identified in O2OA up to 10.0-410. This vulnerability affects unknown code of the file /x_processplatform_assemble_designer/jaxrs/script of the component Personal Profile Page. Executing manipulation of the argument name/alias/description/applicationName can lead to cross site scripting. The attack can be executed remotely. The exploit has been made available to the public and

  2. Oct 19, 2026 · NIST NVD

    Updated

    A weakness has been identified in O2OA up to 10.0-410. This vulnerability affects unknown code of the file /x_processplatform_assemble_designer/jaxrs/script of the component Personal Profile Page. Executing manipulation of the argument name/alias/description/applicationName can lead to cross site scripting. The attack can be executed remotely. The exploit has been made available to the public and

Sources

  • CVE.orgVulnerability recordCVE-2025-9719

    Official CVE identifier

    cve.org
  • NIST NVDVulnerability recordCVE-2025-9719

    A weakness has been identified in O2OA up to 10.0-410. This vulnerability affects unknown code of the file /x_processplatform_assemble_designer/jaxrs/script of the component Personal Profile Page. Executing manipulation of the argument name/alias/description/applicationName can l

    nvd.nist.gov

References

Freshness

Last verified in this catalog Oct 19, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.